High-AIDAS tumors frequently exhibit amplification of known oncogenes, such as MYC, and deletions in tumor suppressor genes, linking AIDAS with oncogenic pathways that drive tumor progression and therapeutic resistance. This evidence concerns the gene MYC and neoplasm.